- Home
- KBR vs MDGL Comparison
KBR vs MDGL Comparison
Compare KBR & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBR
- MDGL
- Stock Information
- Founded
- KBR 1901
- MDGL 2011
- Country
- KBR United States
- MDGL United States
- Employees
- KBR N/A
- MDGL N/A
- Industry
- KBR Military/Government/Technical
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- KBR Industrials
- MDGL Health Care
- Exchange
- KBR Nasdaq
- MDGL Nasdaq
- Market Cap
- KBR 6.3B
- MDGL 6.1B
- IPO Year
- KBR 2006
- MDGL N/A
- Fundamental
- Price
- KBR $49.61
- MDGL $369.84
- Analyst Decision
- KBR Buy
- MDGL Strong Buy
- Analyst Count
- KBR 8
- MDGL 8
- Target Price
- KBR $60.29
- MDGL $439.71
- AVG Volume (30 Days)
- KBR 1.7M
- MDGL 425.4K
- Earning Date
- KBR 07-31-2025
- MDGL 08-05-2025
- Dividend Yield
- KBR 1.33%
- MDGL N/A
- EPS Growth
- KBR 86.03
- MDGL N/A
- EPS
- KBR 2.75
- MDGL N/A
- Revenue
- KBR $8,047,000,000.00
- MDGL $515,547,000.00
- Revenue This Year
- KBR $11.69
- MDGL $286.67
- Revenue Next Year
- KBR $6.58
- MDGL $67.98
- P/E Ratio
- KBR $16.39
- MDGL N/A
- Revenue Growth
- KBR 12.31
- MDGL 3421.98
- 52 Week Low
- KBR $43.89
- MDGL $200.63
- 52 Week High
- KBR $72.60
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- KBR 56.37
- MDGL 72.27
- Support Level
- KBR $48.30
- MDGL $286.44
- Resistance Level
- KBR $50.67
- MDGL $375.67
- Average True Range (ATR)
- KBR 1.29
- MDGL 14.59
- MACD
- KBR 0.32
- MDGL 5.47
- Stochastic Oscillator
- KBR 83.15
- MDGL 93.47
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.